Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Passes Above Fifty Day Moving Average of $10.02

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) shares crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $10.02 and traded as high as $17.50. Pieris Pharmaceuticals shares last traded at $17.39, with a volume of 28,006 shares traded.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Pieris Pharmaceuticals in a research report on Friday, July 12th. They issued a “hold” rating on the stock.

Pieris Pharmaceuticals Trading Up 1.8 %

The company has a market capitalization of $22.95 million, a P/E ratio of -1.46 and a beta of 0.68. The company’s fifty day moving average is $10.16 and its 200 day moving average is $12.11.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its earnings results on Wednesday, May 15th. The biotechnology company reported ($3.95) earnings per share for the quarter. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative return on equity of 57.57%. The company had revenue of $0.05 million for the quarter.

Institutional Trading of Pieris Pharmaceuticals

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Summit Trail Advisors LLC purchased a new position in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 140,000 shares of the biotechnology company’s stock, valued at approximately $26,000. Summit Trail Advisors LLC owned about 0.14% of Pieris Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.